期刊
ANNUAL REVIEW OF GENOMICS AND HUMAN GENETICS, VOL 16
卷 16, 期 -, 页码 369-398出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-genom-090314-050000
关键词
informed decision making; genetic counseling; disability and reproductive rights; regulation and oversight; fetal genome sequencing
资金
- NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R00HG006452, R01HG007074, P50HG003391, P50HG003389] Funding Source: NIH RePORTER
- NHGRI NIH HHS [P50HG03391, R00 HG006452, R01HG007074, R00HG006452, P50HG003389] Funding Source: Medline
Noninvasive prenatal genetic testing (NIPT) for chromosomal aneuploidy involving the analysis of cell-free fetal DNA became commercially available in 2011. The low false-positive rate of NIPT, which reduces unnecessary prenatal invasive diagnostic procedures, has led to broad clinician and patient adoption. We discuss the ethical, legal, and social issues raised by rapid and global dissemination of NIPT. The number of women using NIPT is anticipated to expand, and the number of conditions being tested for will continue to increase as well, raising concerns about the routinization of testing and negative impacts on informed decision making. Ensuring that accurate and balanced information is available to all pregnant women and that access to NIPT is equitable will require policy guidance from regulators, professional societies, and payers. Empirical evidence about stakeholders' perspectives and experiences will continue to be essential in guiding policy development so that advances in NIPT can be used effectively and appropriately to improve prenatal care.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据